Clinical Trials Search
Clinical Trial 20056
Cancer Type: Genitourinary
Study Type: Treatment
NCT#: NCT04300855
Phase: Phase II
Prinicipal Investigator: Nagi Kumar
Study Title
Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS)
Summary
This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D) containing 400 mgs (BID) vs. Placebo, administered for 24 months in a cohort of men with low to intermediate grade prostate cancer managed on active surveillance
Objective
Primary Outcome Measure: To assess the rate of clinical progression in men on active surveillance for prostate cancer (Gleason score (GS) 3+3 OR predominant Gleason grade 3 ( 3+4), ≤ 33% of biopsy cores positive for cancer and ≤ 50% involvement of any one core), treated with standardized GTC (400 mg EGCG bid) vs. placebo for 24 months, with rate of clinical progression defined as a composite outcome on repeat prostate biopsy >33% of biopsy cores positive for cancer or > 50% of any biopsy tissue core positive for cancer or adverse reclassification of Gleason sum > 3+3 or >3+4 respectively at end of study (EOS) biopsy. Secondary outcome measures: In patients randomized to receive GTC (400 mgs EGCG bid) vs. placebo: - Assess the safety of GTC (vs. Placebo) safety by evaluating incidence of adverse events and toxicities, monitored using Common Toxicity Criteria version 5.0 (monthly), CBC, CMP, LFTs at baseline, year 1 and EOS. - Assess bioavailability as indicated by change in EGCG measured in plasma at baseline, year 1 and EOS. - Assess adherence and acceptability to agent by evaluating monthly percentage compliance using agent logs (%) and pill counts monthly. - Assess patient reported symptoms by evaluating change in scores in lower urinary tract symptoms and quality of life from baseline to EOS at baseline, year 1 and EOS. - Assess change in PSA and PSA kinetics (PSA, PSA doubling time and PSA density) from serum from baseline, 6, 12, 18 and EOS. - Assess the change in 17-gene expression panel (Oncotype Dx®) from baseline to EOS using biopsy tissue. - Assess the proportion of men with no cancer in the post-intervention biopsy from baseline to EOS. - Assess changes in the microbiome from baseline to post intervention - With consent of participating subjects, create a specimen repository (serum, stool and prostate biopsies) to test future hypotheses related to prostate cancer, as and when possible.
Therapies
Medications
Sunphenon 90D/placebo ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.